Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis

We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target l...

Full description

Bibliographic Details
Main Authors: Aya Takahashi, Michihisa Moriguchi, Yuya Seko, Toshihide Shima, Yasuhide Mitsumoto, Hidetaka Takashima, Hiroyuki Kimura, Hideki Fujii, Hiroki Ishikawa, Takaharu Yo, Hiroshi Ishiba, Atsuhiro Morita, Masayasu Jo, Yasuyuki Nagao, Masahiro Arai, Tasuku Hara, Akira Okajima, Akira Muramatsu, Naomi Yoshinami, Tomoki Nakajima, Hironori Mitsuyoshi, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Takeshi Okanoue, Yoshito Itoh
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
hepatocellular carcinoma
lenvatinib
early tumor shrinkage
overall survival
response evaluation criteria in solid tumors (recist)
Online Access:https://www.mdpi.com/2072-6694/12/3/754

Internet

https://www.mdpi.com/2072-6694/12/3/754

Similar Items